Research Article: Construction and Identification of an NLR-Associated Prognostic Signature Revealing the Heterogeneous Immune Response in Skin Cutaneous Melanoma
Abstract:
Skin cutaneous melanoma (SKCM) is the most severe dermatologic malignancy, and its incidence has increased worldwide in recent years. SKCM accounts for % of all skin cancer patients, yet it is responsible for roughly % of all skin cancer deaths. Early-stage SKCM (localized or regional) can be surgically removed, and its -year survival rate is over %. The primary treatment method for advanced SKCM is combination therapy, which may include radiotherapy, chemotherapy, and targeted therapy; nevertheless, patient response rates to medication are low, and patients seldom live more than a year. The absence of established predictive indicators restricts the assessment of SKCM disease progression and effective clinical interventions for advanced patients. Hence, searching for biomarkers that could be effective in the prevention and early diagnosis is very important for SKCM.
Introduction:
Skin cutaneous melanoma (SKCM) is the most severe dermatologic malignancy, and its incidence has increased worldwide in recent years. SKCM accounts for % of all skin cancer patients, yet it is responsible for roughly % of all skin cancer deaths. Early-stage SKCM (localized or regional) can be surgically removed, and its -year survival rate is over %. The primary treatment method for advanced SKCM is combination therapy, which may include radiotherapy, chemotherapy, and targeted therapy; nevertheless, patient…
Read more